Methylphenidate extended release - ALZA

Drug Profile

Methylphenidate extended release - ALZA

Alternative Names: Concerta; JNS-001; Oros® methylphenidate

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation
  • Developer Janssen Pharmaceutical KK
  • Class Behavioural disorder therapies; Neuroprotectants; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
  • Mechanism of Action Adrenergic receptor modulators; Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder

Most Recent Events

  • 09 Jun 2014 Registered and launched for Attention-deficit hyperactivity disorder (In adults) in Japan before June 2014 (PO)
  • 24 May 2013 Preregistration for Attention-deficit hyperactivity disorder (in adults) in Japan (PO)
  • 01 Apr 2012 Johnson & Johnson completes phase III trials in Attention-deficit hyperactivity disorder in Japan (NCT01323192, NCT01357993)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top